Somatostatin receptor subtype 4 agonist - Confo Therapeutics
Alternative Names: SSTR4 agonist - Confo TherapeuticsLatest Information Update: 10 Dec 2024
Price :
$50 *
At a glance
- Originator Confo Therapeutics
- Class Analgesics
- Mechanism of Action Somatostatin receptor subtype 4 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Pain
Most Recent Events
- 31 Jul 2024 Confo Therapeutics has patent protection for Confo® technology platform in more than 10 patent families worldwide (Confo Therapeutics website, July 2024)
- 26 Jul 2024 Early research in Pain in Belgium (unspecified route) (Confo Therapeutics pipeline, July 2024)
- 15 Dec 2021 Confo Therapeutics has patent protection for methods for screening GPCRs using ConfoBodies®, GPCR-ConfoBody® complexes, developments of the ConfoBody® platform in ConfoScreen®, ConfoSensor®, ConfoChimer™ and ConfoStructure™ technologies in USA and European Union